Related Experiment Video
Updated: Jun 26, 2025
07:59
Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma
Published on: September 3, 2021
6.4K
Organoids derived from metastatic cancers: Present and future
Xuejing Zheng1, Xinxin Zhang1, Shengji Yu1
1Departments of Orthopedics, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Heliyon
|May 9, 2024
Summary
Patient-derived organoids from metastatic cancers offer a promising model for understanding tumor biology and predicting drug responses. This review explores their potential and challenges in cancer research and therapy.
Area of Science:
- Oncology
- Biotechnology
Background:
- Organoids mimic tissue architecture and function.
- Patient-derived organoids (PDOs) are vital for modeling tumor heterogeneity and drug screening.
- Organoids from metastatic sites are increasingly studied for tumor biology insights.
Purpose of the Study:
- To review the feasibility of culturing organoids from metastatic cancers.
- To evaluate their potential in basic cancer research, drug development, and personalized therapy.
- To explore limitations and challenges of using metastasis organoids.
Main Methods:
- Comprehensive literature review of studies on metastatic cancer organoids.
- Analysis of organoid culturing techniques and applications.
- Evaluation of current research and future prospects.
Main Results:
- Organoids from metastatic sites show potential for modeling tumor biology.
- They can provide insights into therapeutic response prediction.
- Feasibility of culturing varies across different metastatic cancers.
Conclusions:
- Metastatic cancer organoids are valuable tools for advancing cancer research.
- They hold promise for drug development and personalized medicine.
- Addressing current limitations is key to maximizing their utility.
